The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea

The present study investigated the risk of active tuberculosis in patients with inflammatory bowel disease (IBD) treated with vedolizumab or ustekinumab, in actual clinical settings in a country with an intermediate tuberculosis burden. The medical records of 238 patients with IBD who received vedol...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Myeong Geun, Ye, Byong Duk, Yang, Suk-Kyun, Shim, Tae Sun, Jo, Kyung-Wook, Park, Sang Hyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001185/
https://www.ncbi.nlm.nih.gov/pubmed/35411727
http://dx.doi.org/10.3346/jkms.2022.37.e107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001185/
https://www.ncbi.nlm.nih.gov/pubmed/35411727
http://dx.doi.org/10.3346/jkms.2022.37.e107

Ejemplares similares